App-Quantinova.ai

IGHV analysis utilising the Ion GeneStudio™ S5 System and the Oncomine™ BCR IGH‐LR assay – early access experience

Z. Davis - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Outcomes for patients with diffuse large B cell lymphoma in the West of Scotland in the pre‐CAR‐T era

M. Wilson - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population

C. S. Diefenbach - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Follicular lymphoma

Polatuzumab vedotin

Real world, multi‐centre experience of daratumumab monotherapy and response to subsequent treatments in relapsed/refractory myeloma

J. Taube - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

daratumumab Intravenous

Myeloma: not just bones at risk of fracture – assessing the increasing demand on services

T. Freeman - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Plasmacytoma

daratumumab Intravenous

Real world outcomes in multiple myeloma in patients aged 75 and over

D. Hopkins - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

The UK experience of daratumumab monotherapy in relapsed systemic AL amyloidosis

O. Cohen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Orthostatic hypotension

Lenalidomide

Analysis of frontline treatment of non‐transplant elderly myeloma patients in Wales: comparison of bortezomib versus lenalidomide based treatment

C. Bygrave - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

VIM: the results of a phase 1/2 trial of bortezomib, idarubicin and melphalan in relapsed or refractory multiple myeloma

K. Boyd - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Bortezomib

Risk of pneumonia and tolerability in patients with multiple myeloma treated with daratumumab: a systematic review and combined meta‐ analysis of six phase III randomised controlled trials

T. W. Htut - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Autologous stem cell transplant for multiple myeloma patients above 65 years of age

A. Cooper - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Multiple Myeloma

Cyclophosphamide

Real world experience of tandem autologous stem cell transplant for high risk multiple myeloma at a single UK centre

H. Richards - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Acute lung injury

Melphalan

Panobinostat in combination with bortezomib and dexamethasone for heavily pre‐treated myeloma: a UK real‐world multi‐centre cohort

N. Maouche - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

Impact of change of mobilisation method on adequacy of stem cell collection in multiple myeloma patients – single centre experience

V. Anandhan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Plerixafor

Feasibility and safety of 90‐min rapid rate daratumumab in myeloma: a prospective multicentre observational study

N. Maouche - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Chlorphenamine

A single centre review of bortezomib home‐administration in myeloma patients: portsmouth experience

K. De Abrew - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Bortezomib

End of life management of patients with myeloma at University Hospitals of Birmingham

B. Salhan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Real‐world outcomes of daratumumab monotherapy in relapsed/refractory myeloma

N. Maouche - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

Lenalidomide

Prevention and management of steroid‐induced hyperglycaemia in outpatient myeloma chemotherapy ‐ a tertiary centre audit and quality improvement project

P. Vassallo - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Dexamethasone

INSIGHT MM study of routine clinical practice in multiple myeloma: analysis of duration of therapy and treatment sequencing in UK patients

G. Cook - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

Filters

45280 Abstracts